$MRNA (+8,19 %)
| Moderna Q3 Earnings Highlights:

🔹 Revenue: $1.86B (Est. $1.25B) 🟢

🔹 COVID-19 Vaccine Revenue: $1.8B (Est. $1.2B) 🟢

🔹 Cash & Cash Equivalents: $1.64B (Est. $2.93B) 

🔹 RSV Vaccine Revenue: $10M

🔹 Net Income: $13M vs. net loss of $3.6B YoY

FY24 Outlook 

🔹 Reaffirmed Revenue: $3B - $3.5B (Est. $3.21B)

🔹 Cost of Sales: Expected 40-45% of product sales

🔹 R&D Expenses: $4.6B - $4.7B (revised down)

🔹 Capital Expenditures: $1.2B

Financial Metrics

🔹 Cost of Sales: $514M; 28% of product sales, down from 128% YoY due to lower inventory write-downs

🔹 R&D Expenses: $1.1B, down 2% YoY

🔹 SG&A Expenses: $281M; down -36% YoY

Business Highlights

🔸 $1.8B in Spikevax® sales; 40% U.S. market share for COVID-19 season-to-date

🔸 Expanded executive leadership and secured early approvals for COVID-19 vaccine

🔸 Initiated Phase 3 trials for norovirus and flu vaccines

🔸 Positive Phase 3 data for RSV and Flu/COVID combination vaccines